As the therapeutic architecture of targeted oncology grows exponentially more complex, the state of ADC Manufacturing reveals a massive industry pivot. Producing an antibody-drug conjugate is notoriously difficult; it requires large-scale biologic production, specialized chemical synthesis, and ultra-sterile bioconjugation facilities. As the market races toward a projected $71 billion valuation by 2031, specialized Contract Development and Manufacturing Organizations (CDMOs) have become the lifeblood of ADC Manufacturing. [1]
Why CDMOs Dominate ADC Manufacturing
The defining feature of modern ADC Manufacturing is the consolidation of supply chains. Because fewer than 30% of biopharma innovators possess all required capabilities in-house, they are aggressively outsourcing to “one-stop-shop” facilities to reduce risks.
Scaling HPAPI Production in ADC Manufacturing
Modern therapies utilize high-potency active pharmaceutical ingredients (HPAPIs) like Exatecan. Handling these toxins safely requires OEB 5-level containment protocols. To meet commercial demand, global CDMOs like TOT Biopharm have rapidly expanded their production lines to accommodate the sheer volume required for global ADC Manufacturing. [2] This expansion is critical to alleviating the global bioconjugation bottleneck.
Licensing Shifts Impacting ADC Manufacturing
Beyond physical production, the financial side of the sector is heavily defined by “East-to-West” strategic licensing. Western pharma companies are increasingly licensing de-risked, clinical-stage assets from Chinese biotech firms to bypass years of early R&D.
The Crescent Biopharma and Kelun-Biotech Deal
A landmark example of this trend is the partnership between Crescent Biopharma and Kelun-Biotech. Crescent successfully licensed CR-003 (SKB105), an ITGB6-targeted ADC utilizing a proprietary irreversible conjugation technology. In January 2026, Kelun-Biotech announced that the IND application for this asset was officially approved, shifting the focus entirely to clinical ADC Manufacturing and scale-up in the US and Europe. [3]
2026 Cross-Border Licensing Milestones
| Western Licensee | Original Developer | Key Asset | 2026 Milestone |
|---|---|---|---|
| Crescent Biopharma | Kelun-Biotech | CR-003 (SKB105) | IND Approved (Jan 2026) [3] |
| ArriVent BioPharma | Aarvik Therapeutics | ARR-217 | Phase 1 Initiation [4] |